Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam Tosilate for Sedation in Upper GI Endoscopy
NCT03003884Phase 2Completed
- Sponsor
- Hengrui
- Start
- Nov 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of remimazolam in Procedural sedation (PS) (5 arms), sponsored by Hengrui. Primary endpoint: Successful Sedation Rate at 3 hours. Started Nov 2016; status: completed.
02
Drugs
remimazolam
03
Conditions
Procedural sedation (PS)
Beyond the preview
Go deeper on NCT03003884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003884.